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Eukaryotic chromatin is subject to multiple posttranslational histone modifications
such as acetylation, methylation, phosphorylation, and ubiquitination. These various
covalent modifications have been proposed to constitute a “histone code,” playing im-
portant roles in the establishment of global chromatin environments, transcription,
DNArepair, andDNAreplication.Among thesemodifications, histonemethylation spec-
ifies regulatory marks that delineate transcriptionally active and inactive chromatin.
Thesehistonemethylmarkswere considered irreversible; however, recent identification
of site-specific histone demethylases demonstrates that histone methylation is dynam-
ically regulated, which may allow cells to rapidly change chromatin conformation to
adapt to environmental stresses or intrinsic stimuli.Ofmajor interest is the observation
that these histone demethylase enzymes, which are in the Jumonji gene family, require
oxygen to function and, in some cases, are induced by hypoxia in an HIFα-dependent
manner. This provides a new mechanism for regulation of the response to hypoxia.
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Introduction
Physiological or pathological hypoxia is well-
recognized to initiate a gene transcription
program of adaptation via hypoxia-inducible
factor (HIF), the master regulator of oxygen
homeostasis. HIF is a heterodimer consisting
of alpha and beta subunits, whose activity is
dependent on the availability of HIFα. Three
HIFα subunits, includingHIF-1α, HIF-2α, and
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HIF-3α, have been identified.1 The role ofHIF-
3α is not clear, but it can function as an inhibitor
of transcription since it lacks the transcriptional
activation domain.2 HIF-1α or HIF-2α com-
plexes with HIF-1β (ARNT), forming the com-
petent transcription factor HIF-1 and HIF-2,
respectively. HIFα induction is mainly regu-
lated by an oxygen-dependent mechanism.3 In
normoxia, HIFα is posttranslationally modi-
fied by prolyl hydroxylases (PHDs).4 The pro-
line hydroxylation of HIFα results in binding of
von Hippel−Lindau (VHL) protein, a compo-
nent of an E3 ubiquitin ligase complex that
targets HIFα for ubiquitination and protea-
somal degradation.4 In addition to the pro-
lyl hydroxylation by PHDs, one asparagine
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residue in the C-terminal transactivation do-
main is also hydroxylated by an asparaginyl
hydroxylase, termed “factor inhibiting HIF-1
(FIH1).”4 Hydroxylation by FIH1 blocks the
binding of transcriptional cofactors, such as
p300/CBP, to the transactivation domain,
thereby suppressing the transcriptional activity
of HIF in normoxia. The PHDs and FIH1 are
Fe(II)- and 2-oxoglutarate-dependent dioxyge-
nases and their activities require the presence
of molecular oxygen.4 Therefore, hydroxyla-
tion of HIFα by PHDs and FIH1 is inhibited in
hypoxia, and HIFα is thus stabilized and acti-
vated. The stabilized HIFα undergoes nuclear
translocation, dimerizes with HIF-1β, and as-
sociates with transcriptional co-activators, such
as p300/CBP and SRC1, to activate the gene
transcription. Despite their structural similar-
ity, HIF-1α and HIF-2α play different roles in
embryogenesis and exert differential functions
in cells.1
Recent studies suggest that hypoxia
can cause chromatin alterations, such
as global deacetylation, and increase in
H3K9me3/me2.5 Increased H3K4me3 levels
and decreased H3K27me3 levels were also
observed at promoters of hypoxia-regulated
genes.5 These findings suggest that, besides
HIF-mediated gene transcription, modulation
of histone methylation via an epigenetic
mechanism is another device that cells use to
adapt to hypoxia. Interestingly, the Jumonji C
(JmjC) domain-containing histone demethy-
lases JMJD1A and JMJD2B are induced by
hypoxia in an HIFα-dependent manner.6–8
We further confirmed that JMJD1A in breast
cancer cell MCF7 and glioblastoma cell U87 is
upregulated by hypoxia in an HIFα-dependent
manner (Fig. 1). JMJD1A can be induced by
overexpression of HIF-1α or HIF-2α, while
loss of HIF-1α or HIF-2α causes reduction of
JMJD1A. These data indicate that JMJD1A is
commonly regulated by HIF-1α and HIF-2α.
Nevertheless, we have also found that JMJD1A
induction is dependent on HIF-1α alone in
another breast cancer cell line T47D (Fig. 1F),
reflecting a cell-type specific effect. These
recently identified HIF targets shed new light
on the regulatory mechanisms of HIFα, which
might tune hypoxic response via an epigenetic
regulation mediated by histone demethylases.
Histone Demethylases Induced
by Hypoxia
Histone lysine demethylase is composed
of two families, including LSD1 and JmjC
domain-containing proteins.9 LSD1 is a flavin
adenine dinucleotide (FAD)-dependent en-
zyme,10 while most JmjC domain-containing
histone demethylases are dioxygenases and
phylogenetically similar to FIH1, whose activ-
ities require Fe(II), a-ketoglutarate, and oxy-
gen;9 hence, potentially, their enzyme activi-
ties could be affected by oxygen tension. There
are about 30 JmjC domain-containing proteins
in human beings (Fig. 2). Although JMJD1A
and JMJD2B have been demonstrated to be
HIF targets, other JmjC domain-containing
proteins may also be upregulated by hypoxia
or HIF. Based on the published gene expres-
sion profile data, we identified that seven ad-
ditional JmjC domain-containing proteins, in-
cluding JMJD1B, JMJD2C, JMJD6, PLU-1,
SMCX, RBP2, and KIAA1718, could be up-
regulated by hypoxia (Fig. 2).
A recent study using chromatin immuno-
precipitation (ChIP) sequencing approach also
found that 17 out of 22 JmjC family genes were
upregulated by hypoxia,11 four of which (in-
cluding PLU-1, JMJD1A, JMJD2B, JMJD2C)
were direct HIF-1 targets. The biological func-
tions of these histone demethylases in hypoxia
are still unknown. As JmjC domain-containing
histone demethylases have already been re-
viewed,9,12–14 here we only focus on the HIF-
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Figure 1. HIFα-dependent induction of JMJD1A. (A) MCF7 and U87 cells were incubated
in hypoxia for 16 h. Quantitative real-time PCR (top panel) and Western blotting (bottom
panel) were used for assessment of JMJD1A expression. (B) PC3 cells that highly express
HIF-1α or HIF-2α were used to assess the JMJD1A expression with indicated antibodies.
(C, D) MCF7 cells were transfected with siRNAs against HIF-1α and HIF-2α. JMJD1A protein
and mRNA levels were assessed by Western blotting (C) and quantitative real-time PCR (D),
respectively. (Student’s t test ∗∗P < 0.01.) (E, F) U87 cells and T47D cells were transfected
with siRNAs against HIF-1α and HIF-2α. JMJD1A mRNA levels were asessed by PCR; 18S
RNA was used as the loading control.
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Figure 2. Phylogenetic tree analysis of JmjC domain-containing proteins. (A) Phylogenetic
tree was constructed according to the JmjC domain sequence. The hypoxic induction data
summarized here is based on previous publications and analysis of published microarray
data. Hairless induction by hypoxia, which has not been reported, was validated by quantati-
tive PCR. The histone demethylases that can be directly regulated by HIF-1α are highlighted
in pink. (B) Histone H3 tails are subject to various posttranslational modifications, including
methylation. Specifically, the methyltransferases and histone demethylases that are respon-
sible for modification on specific residues are shown, in which hypoxia-inducible histone
demethylases are highlighted in pink.
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specific H3K9me2/me1 demethylase,15 which
was originally identified as amale germ-specific
transcript16 and is therefore most prominently
expressed in testes.15 JMJD1A has been shown
to interact with ER71,17 a transcription factor
that is expressed in the testes of adult mice and
during embryogenesis and impairs the ability
of ER71 to activate transcription from the
matrix metalloproteinase-1 promoter,17 sug-
gesting that JMJD1A may play a role in male
germ cell development. Indeed, a genetrap
mouse model shows that JMJD1A is essential
for spermatogenesis by in that it positively
regulates gene expression of transition nuclear
protein (Tnp1) and protamine 1 (Prm1) via
demethylation of H3K9 marks from these
genes promoters.18
Using a knockout mouse the same re-
search group demonstrated that JMJD1A also
plays an essential role in regulating metabolic
gene expression and normal weight control.19
They found that loss of JMJD1A disrupted β-
adrenergic-stimulated glycerol release and oxy-
gen consumption in brown fat, decreased fat
oxidation and glycerol release in skeletal mus-
cles and resulted in obesity and hyperlipidemia
in mice.19 Mechanistically, JMJD1A induced
by adrenergic stimulation directly regulates ex-
pression of peroxisome proliferator-activated
receptor α (PPARα) and Ucp1 by removing
H3K9me2 marks on PPAR responsive ele-
ment (PPRE) of PPARα and Ucp1 genes. More-
over, upon β-adrenergic activation, JMJD1A
also can facilitate the recruitment of PPAR
and RXRα and their co-activators Pgc1α,
CBP/p300, and SRC1 to PPRE of Ucp1 gene,
indicating that JMJD1A not only serves as a
histone demethylase but also exerts transcrip-
tional co-activator function.
Another study shows that JMJD1A is associ-
ated with the cardiac and smooth muscle cell
(SMC)-specific transcription factor myocardin
and the related proteins MRTF-A and MRTF-
B20; binds to SMC-specific gene promoters;
and regulates TGFβ-mediated activation of
these genes, suggestive of a role of JMJD1A in
SMC differentiation. Knockdown of JMJD1A
attenuates TGFβ-induced upregulation of en-
dogenous SM myosin heavy chain expres-
sion, concomitant with increased H3K9me2
at the SMC differentiation marker gene pro-
moters and with inhibition of MRTF-A-
dependent transactivation of the SMC-specific
transcription.20
JMJD1A has been implicated in regulation
of self-renewal of embryonic stem (ES) cells.21
The ES cell transcription factor Oct4 positively
regulates JMJD1A and JMJD2C expression.
Depletion of JMJD1A leads to ES cell differen-
tiation, which is accompanied by a reduction in
the expression of ES cell-specific genes and an
induction of lineage marker genes.21 JMJD1A
demethylates H3K9me2 at the promoter re-
gions of pluripotency-associated genes, includ-
ing Tcl1, Tcfcp2l1, and Zfp57, and it positively
regulates the expression of these genes.21 One
study indicates that JMJD1A can also promote
ES cell-induced reprogramming of somatic
cells by enhancing re-activation of Oct4.22
JMJD1A has been found to be a STAT3 down-
stream gene inmouse ES cells.23 STAT3 activa-
tion is believed to be important for the mainte-
nance of pluripotency by Leukemia Inhibitory
Factor (LIF), further suggesting that JMJD1A
might be a critical signaling molecule under-
lying the maintenance of pluripotency in ES
cells.
Although the role of JMJD1A induction in
hypoxia remains unknown, implications of hy-
poxia and HIF in regulation of embryonic
stem cells and progenitor cells suggest that
JMJD1A might be involved in maintenance
or differentiation of hypoxic stem cells or hy-
poxic cancer stem cells. To test this hypoth-
esis, we cultured HCT116 colon cancer cells
as spheroids, dispersed them into single cells,
and then sorted them using FACS according to
the markers of CD133 and CA9, which rep-
resent stem cell marker and hypoxia markers,
respectively.We found that three populations of
cells, CD133+ CA9+, CD133+, and CD133−
cells, differentially express JMJD1A with high-
est levels in CD133+ CA9+ populations and
lowest levels in CD133− populations (Fig. 3).
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Figure 3. JMJD1A is more highly expressed
in CD133+CA9+ HCT116 colon cancer cells. (A)
HCT116 colon cancer cells are spheroid showing hy-
poxia regions stained after incubating spheroids with
pimonidazole (PIMO) which is matched with staining
for carbonic anhydrase IX (CA9). (B) Cells derived
from the spheroids were sorted by FACS according
to CD133 and CA9 markers. (C) Western blotting
shows that JMJD1A is highly expressed in CD133+
cancer cells and more highly in hypoxic CD133+
cancer cells.
These data suggest that cancer cells with stem
cell-like properties can highly express JMJD1A,
especially for those hypoxic stem-like cancer
cells.
Clinical Studies of JMD1A
Yamane et al. has shown that JMJD1A is
highly expressed in prostate cancer and has
been involved in demethylation of H3K9me2
of androgen receptor (AR) target genes includ-
ing PSA,NKX3.1, andTMPRSS22,15 suggesting
that JMJD1A might play an important role in
prostate cancer development. We have found
that JMJD1A is expressed in human cancers
such as glioblastoma and breast cancer in vivo,
and expression is associated with the hypoxic
marker CA9 (Fig. 4). Nonetheless, tissue mi-
croarray analysis reveals that there is no signif-
icant change in JMJD1A expression between
various normal tissues and tumors overall (data
not shown), suggesting thatmoderate upregula-
tion of JMJD1A expression might be limited to
themost hypoxic areas expressingHIFα. As hy-
poxia or HIF each plays important roles in can-
cer metastasis and resistance in chemotherapy
and radiotherapy, whether JMJD1A is involved
in these processes remains to be studied.
Enzyme Activity of JMJD1A in Hypoxia
JMJD1A protein bears an LXXLL motif
that is a signature of protein−protein inter-
action with nuclear receptors. Thus, JMJD1A
was found to interact with the AR in a ligand-
dependent manner.15 Inhibition of JMJD1A
expression in the prostate cancer cell line
LnCaP led to an increase inH3K9me2 in a sub-
set of AR target genes.15 These results show that
JMJD1A acts as a co-activator of AR-mediated
transcription. But whether and how JMJD1A
regulates gene expression in hypoxia remains
to be elucidated.
As JMJD1A is a dioxygenase whose activ-
ity requires the presence of oxygen, hypoxia
might limit its enzymatic function. However, a
recent study reveals that 1%O2 does not inhibit
the histone demethylase function of JMJD1A8;
even 0.2% O2 does not completely inhibit its
enzymatic activity,8 suggesting that, like FIH1,
JMJD1A can tolerate relatively low oxygen.
This observation raises an important question:
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Figure 4. JMJD1A expression is associated with hypoxia in cancer. (A, B) JMJD1A
and HIF-1α data from the Sun et al. study53 were reanalyzed using the Prism program. (C,
D) JMJD1A expression in breast cancer and glioblastoma samples were analyzed using
immunohistochemistry (magnifiction ×20).
Does JMJD1A exert its function in hypoxia
via a histone demethylase-dependent manner
or just act as a transcriptional co-activator (or
co-repressor in other circumstances) via inter-
action with other transcription factors such as
nuclear receptors in an enzyme-independent
way? Probably both mechanisms can be im-
plicated in hypoxia since its histone demethy-
lase function is not inhibited. Hairless, another
member of JMJD1 subfamily, which has no re-
ported histone demethylase activity, can exert
as a transcriptional co-repressor for various nu-
clear receptors including vitamin D receptor
(VDR), thyroid hormone receptor (THR), and
retinoic acid receptor-related orphan receptors
(ROR).24,25 Therefore, JMJD1A could also po-
tentially regulate gene transcription in hypoxia
independent of its histone demethylase activity.
Identification of JMJD1A target genes in hy-
poxia is necessary to answer these questions.
Further analysis using ChIP would allow us to
assess whether histone methylation status can
be modulated by JMJD1A in hypoxia. ChIP-
sequencing, or ChIP-on-chip, may greatly fa-
cilitate the global identification of JMJD1A
targets.
Considering that JMJD1A can regulate gene
expression and can be induced in hypoxia,
one might expect that JMJD1A could modu-
late transcriptional activities of HIF-1. How-
ever, we used qRT-PCR to assess about 20
HIF-regulated genes and found that none of
them can be significantly affected by JMJD1A
knockdown in MCF7 cells (data not shown),
suggesting that either JMJD1A only regulates
a small subgroup of genes that are associated
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Figure 5. Subcellular localization of JMJD1A. (A, B) MCF7 cells were incubated in hy-
poxia for 16 h. Immunofluorescence (A) and subcellular fractionation (B) were used to assess
the localization of JMJD1A. (C, D, E) Immunohistochemistry analysis of JMJD2B in tumor sec-
tions, which shows predominant localization in cytoplasmic, nuclear, or both compartments.
with HIF that we failed to select or JMJD1A
separately regulates a specific group of genes
that are distinct from HIF1-regulated genes.
Subcellular Localization of JMJD1A
The ascribed histone demethylase function
of JMJD1A may make us expect that JMJD1A
should be dominantly localized in nucleus to
modulate histone methyl marks. Surprisingly,
we have found that in a large proportion of
normal tissues and clinical tumor samples,
JMJD1A is localized in both cytoplasm and
nucleus and this is also confirmed in cancer
cells although JMJD1A can be dominantly lo-
calized in nucleus or cytoplasm (Fig. 5). Hy-
poxia (1% O2) did not change the cytoplas-
mic distribution of JMJD1A in MCF7 cells.
These observations raise another important
question: Does JMJD1A have physiological
functions in cytoplasm either in normoxia or
hypoxia? Although it remains to be answered
for this question, subcellular localization of
JMJD1A is probably an important mechanism
to regulate its function. We want to further
extend this question; does JMJD1A possess
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Figure 6. Potential roles of JMJD1A.
histone-independent demethylase function ei-
ther in nucleus or cytoplasm? Recent studies
have shown that lysines on non-histone pro-
teins such as TAF1026 and p5327 can be methy-
lated. G9a, the histone H3 lysine methyltrans-
ferase can be automethylated.28,29 There is no
question that these methylations can be re-
versed by corresponding demethylases. Indeed,
lysine methylation of p53 can be removed by
LSD1.30 Identification of non-histone targets
of JMDJ1A using proteomics could help to an-
swer this question.
In summary, JMJD1A is important for
spermatogenesis, metabolism regulation, self-
renewal of stem cells, and possibly involved
in smooth muscle cell differentiation (Fig. 6).
JMJD1A is also involved in cancer and hypoxic
stress; however, the role of JMJD1A in hypoxia
is still unknown, and further studies need to
be conducted to examine the biological func-
tions of JMJD1A in hypoxia and to dissect the
molecular mechanism by which JMJD1A reg-
ulates gene transcription in hypoxia.
JMJD2
The JMJD2 subfamily consists of four mem-
bers, including JMJD2A, JMJD2B, JMJD2C,
and JMJD2D, which are capable of remov-
ing H3K9me3/me2 and H3K36me3/me2
marks.31–33 Amongst these four members,
JMJD2B and JMJD2C have been shown to
be upregulated in hypoxia7,8 and their hy-
poxic induction is HIF-dependent as evidenced
by ChIP-sequencing results.11 We have found
that JMJD2B induction is HIF-1α-dependent
(Fig. 7), and JMJD2B expression is associated
with hypoxia marker CA9 in brain tumors
(Fig. 7). The biological functions of JMJD2
are not very clear. Enforced expression of
JMJD2B and JMJD2C significantly decreases
global H3K9me3 and H3K9me2 levels and
delocalizes HP1, suggesting that JMJD2 fam-
ily proteins are capable of reorganizing het-
erochromatin.31,32 Like JMJD1A, when over-
expressed in hypoxia, JMJD2B protein is still
capable of removing H3K9me3 mark,8 indi-
cating that JMJD2B can exert its demethylase
function in hypoxia.
JMJD2C, together with JMJD1A, plays an
important role in self-renewal of stem cells.21
Again, it is very possible that JMJD2C may
be involved in maintenance or differentiation
of hypoxia-regulated stem cells and stem-like
cancer cells. JMJD2C was found to be am-
plified in squamous cell carcinoma.34,35 A re-
cent aGCH study also shows that JMJD2B
and JMJD2C are amplified in medulloblas-
tomas,36 suggesting that JMJD2B and JMJD2C
have oncogenic functions. Consistent with this,
JMJD2A, JMJD2B, and JMJD2C are overex-
pressed in cancer, and inhibition of JMJD2A
and JMJD2C affects cellular growth.31 How-
ever, how JMJD2 exactly regulates cell pro-
liferation remains to be elucidated. A func-
tional interaction between JMJD2C and the
AR in prostate carcinomas has been reported
recently.37 JMJD2C can bind to the AR and
acts as an essential co-activator of AR-induced
transcription, suggesting that JMJD2Cplays an
important role in prostate cancer progression.
Whetstine et al. demonstrated that deple-
tion of the Caenorhabditis elegans JMJD2 ho-
molog, CeJMJD2, resulted in a global increase
of H3K9me3 levels, localized H3K36me3 to
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Figure 7. HIF-1α-dependent regulation of JMJD2B. (A, B) MCF7 and U87 cells were
incubated in hypoxia for 16 h. Quantitative real-time PCR (A) and Western blotting (B) were
used for assessment of JMJD2B expression. (Student’s t test ∗∗ P < 0.01.) (C) MCF7 cells
were transfected with siRNAs against HIF-1α and HIF-2α. JMJD2B protein were assessed
by Western blotting. (D) JMJD2B expression in glioblastoma samples were analyzed using
immunohistochemistry (magnification ×20).
meiotic chromosomes, and activation of p53-
dependent germline apoptosis.33 p53 has been
shown to play an important role in apopto-
sis in hypoxic tumor cells as apoptosis is sig-
nificantly reduced when tumors express mu-
tant p53.38,39 Therefore, whether JMJD2B and
JMJD2C are entangled in p53-mediated apop-
tosis in response to hypoxia is another key
question.
Genomic amplification of JMJD2B and
JMJD2C inmedulloblastoma ismutually exclu-
sive,36 suggesting that JMJD2B and JMJD2C
may regulate the same signaling pathway.How-
ever, the fact that hypoxic induction of JMJD2B
and JMJD2C can occur in the same cancer
cells suggests that JMJD2B and JMJD2C may
not completely function redundantly but have
specific targets. How JMJD2B and JMJD2C
regulate, in coordination, gene transcription in
response to hypoxia needs to be answered. Sim-
ilarly, the hypoxic induction of JMJD1A and
JMJD2C, both of which are involved in self-
renewal of ES cells and interaction with AR in
prostate cancer cells, raises an interesting ques-
tion: Do JMJD1A and JMJD2C cooperatively
work to regulate gene expression, or could both
be recruited to the same gene promoter, which
is AR-regulated? Considering that JMJD1A
and JMJD2C demethylate H3K9me2/me1
and H3K9me3/me2, respectively, it is possible
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that both enzymes are sequentially or together
recruited to the same loci to exert their hi-
stone demethylase function or transcriptional
activities.
H3K36me3/me2 is associated with tran-
scriptional elongation and suppresses inap-
propriate transcription within the body of
genes,40 while the H3K9me3/me2 is associ-
ated with transcriptional repression and het-
erochromatin. Therefore, in one way, JMJD2
would demethylate H3K36me3/me2 and in-
hibit transcription elongation; in another way,
JMJD2 would promote gene transcription by
demethylating H3K9me3/me2. Understand-
ing how JMJD2 integrates the milieux of chro-
matin structure that specifically activate or sup-
press gene transcription in hypoxia remains a
challenge.
PLU-1
PLU-1 (KDK5B, JARID1B) is a mem-
ber of histone lysine demethylase 5 (KDM5)
family,13 which specifically demethylates
H3K4me3/me2 and therefore plays a tran-
scriptional repressor role.41,42 PLU-1 expres-
sion ismainly restricted to testes in normal adult
tissues.43,44 However, high expression of PLU-1
is also seen in the murine pregnant mammary
gland and embryonic mammary bud,45 sug-
gesting that PLU-1 is involved in development
and differentiation of mammary gland. Consis-
tent with the role in mammary glands, PLU-1
is highly expressed in 90% of invasive ductal
breast carcinomas regardless of HER2 status,
although PLU-1 was identified in a screen for
genes regulated by HER2.44,46 PLU-1 is able
to promote breast cancer cell proliferation by
facilitating G1/S phase transition.41 Loss of
PLU-1 by knocking down gene expression sup-
presses tumor growth of mammary carcinoma
cells in nude mice.41 PLU-1 has also been asso-
ciated with prostate cancer.42 PLU-1 is associ-
ated with AR and regulates its transcriptional
activity.42
A recent in vitro study suggests that PLU-1
may play a role in the choice between prolifera-
tion and differentiation during development.47
Transient overexpression of PLU-1 in ES cells
decreases the expression of cell fate modula-
tor genes such as Egr1, p27Kip1, and BMI1.47
PLU-1 is able to reduce the terminally differen-
tiated cells and increase proliferating progen-
itors via blocking of the upregulation of cell
lineage markers and maintenance of cyclins,
thereby allowing cells to escape differentiation
and remain uncommitted.47 Microarray analy-
sis reveals that PLU-1 suppresses BRCA1, met-
allothionein genes and genes involved in regu-
lation of M phase of the mitotic cell cycle.48
PLU-1 can directly interact with histone
deacetylases (HDACs), such as HDAC4.49
HDAC4 and PLU-1 are co-expressed in the
pregnant and involuting mammary gland, and
both are silenced at lactation and expressed
in breast cancers.49 PLU-1 also interacts with
brain factor-1 (BF-1) and paired box 9 (PAX9)
transcription factors via a conserved sequence
motif.50 Mutation of this motif in BF-1 and
PAX9 abolished PLU-1 co-repression activ-
ity.50 Both BF-1 and PAX are known to inter-
act with members of the Groucho co-repressor
family, potentially supporting a role for PLU-
1 in Groucho-mediated transcriptional repres-
sion.Despite the importance of PLU-1 in breast
cancer, the hypoxic role of PLU-1 is unknown
and the relationship of hypoxic induction of
PLU-1 and mammary gland differentiation or
breast cancer progression has not been studied
yet.
Conclusions
The findings of hypoxic induction of histone
demethylases have important implications in
cancer biology. As some JmjChistone demethy-
lases, such as JMJD2B and JMJD2C, have
oncogenic functions, and have been shown to
be amplified in cancers,35,36 HIFα-mediated in-
duction of these oncogenes further confirms
that HIFα plays an important role in can-
cer progression. The JmjC histone demethy-
lases are dioxygenases, whose activities require
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Fe(II) and 2OG. These enzymes can be tar-
geted by small compounds, for example, via
competing with Fe(II) or 2-OG, binding or dis-
placing methyl peptide from the pocket that
accommodates the histone methyl marks. The
crystal structure of JmjC domain of JMJD2A
has been solved,51,52 the catalytic core of his-
tone demethylase has very high homology to
JMJD2B and JMJD2C. This may accelerate
the development of small molecules against
JMJD2B and JMJD2C.
Since hypoxia can induce multiple histone
demethylases, what are the biological conse-
quences for the interactions in hypoxia? The
roles of the histone methyltransferases, which
may exert opposite effects, have not beenwidely
studied yet. Elucidation of epigenetic regulation
via histone methylation and demethylation in
response to hypoxia may provide new insight
for understanding of how cancer cells evolve
under environmental stress and provide ratio-
nale for development of novel cancer thera-
peutic drugs against the methyltransferases or
histone demethylases.
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